Epidemiology and risk factors of the prostate cancer;Epidemiologia oraz czynniki ryzyka rozwoju raka gruczołu krokowego

Polski Merkuriusz Lekarski

Volumn 33, Issue 195, 2012, Pages 163-167

  Stasiewicz, Dominika ^a   StarosŁawska, Elzbieta ^a   Brzozowska, Anna ^b   Mocarska, Agnieszka ^a   Łosicki, Marek ^a   SzumiŁo, Justyna ^b   Burdan, Franciszek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Department of Oncology ^*  (Poland)

Author keywords

Environmental factors; Etiology; Genetics; Prostate cancer; Risk factors

Indexed keywords

EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; HEALTH; HUMAN; INCIDENCE; MALE; PROSTATE TUMOR; REVIEW; RISK FACTOR;

CAUSALITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; WORLD HEALTH;

EID: 84871881830     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Akinloye O., Gromoll J., Simoni M.: Variation in CAG and GGN repeat lengths and CAG/GGN haplotype in androgen receptor gene polymorphism and prostate carcinoma in Nigerians. Br. J. Biomed. Sci., 2011; 68; 138-142.
2. Bosland M., Ford H., Horton L.: Induction of a high incidence of ductal prostate adenocarcinoma in NBL and Sprague Dawley rats treated with estrdaiol-17ß or diethylstilbestrol in combination with testosterone. Carcinogenesis, 1995; 16; 1311-1317.
3. Bratt O.: Hereditary prostate cancer: clinical aspects. J. Urol., 2002; 168; 906-913.
4. Brauer H., Libby T., Mitchell B. et al.: Cruciferous vegetable supplementation in controlled diet study alters the serum peptidome in a GSTM1- genotype dependent manner. Nutr. J., 2011; 10; 11.
5. Cook L., Goldoft M., Schwartz S. et al.: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol., 1999; 16;, 152-155.
6. Crum N., Spencer C., Amling C.: Prostate carcinoma among men with human immunodeficiency virus infection. Cancer, 2004; 101; 294-299.
7. De Marzo A., Marchi V., Epstein J. et al.: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol., 1999; 155; 1985-1992.
8. De Marzo A., Meeker A., Zha S. et al.: Human prostate cancer precursors and pathobiology. Urology, 2003; 62; 55-62.
9. Ewing Ch., Ray A., Lange E. et al.: Germline mutations in HOXB13 and prostate cancer risk. N. Engl. J. Med., 2012; 366; 141-149.
10. Ferlay J., Shin H., Bray F. et al.: Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France; International Agency for Research on Cancer; 2010. www.globocan.iarc.fr GLOBOCAN 2008 v1.2 04/05/y2012/.
11. Gronberg H., Damber L., Damber J.: Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer, 1996; 77; 138-143.
12. Heidenreich A., Bastian P., Bellmunt S. et al.: Guidelines on prostate cancer. European Association of Urology 2012. www.uroweb.org/gls/pdf/ 08 Prostate Cancer LR March 13th 2012.pdf/.
13. Hsing A., Chokkalingam A.: Prostate cancer epidemiology. Front. Biosci., 2006; 11; 1388-1413.
14. Huggins C., Hodges C.: Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1941; 1; 293-297.
15. Jacobson E., Hugo E., Borcherding D. et al.: Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discov. Med., 2011; 11; 315-324.
16. Labrie F.: Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat. Rev. Urol., 2011; 8; 73-85.
17. Lawence E., Gnanapragasam V., Priest A. et al.: The emerging role of diffusion-weighted MRI in prostate cancer management. Nat. Rev. Urol., 2012; 9; 94-101.
18. Liang C., Liu Q., Zhou F. et al.: Etiologic correlations of prostate cancer in Guangdong, China to family history of cancers, and sexual and marital factors - a case control study. Chin. J. Cancer, 2007; 26; 484-488.
19. Merrimen J., Jones G., Walker D. et al.: Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J. Urol., 2009; 182; 485-490.
20. Nelles J., Hu W., Prins G.: Estrogen action and prostate cancer. Expert. Rev. Endocrinol. Metab., 2011; 6; 437-451.
21. Platz E., Leitzmann M., Michaud D. et al.: Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res., 2003; 63; 8542-8548.
22. Prins G., Huang L., Birch L. et al.: The role of estrogens in normal and abnormal development of the prostate gland. Ann. NY Acad. Sci., 2006; 1089; 1-13.
23. Prins G., Birch L., Habermann H. et al.: Influence of neonatal estrogens on rat prostate development. Reprod. Fertil. Dev., 2001; 13; 241-252.
24. Przybyszewski W., Rzeszowska-Wolny J.: Stres oksydacyjny w procesach przerostu i kancerogenezy gruczołu sterczowego. Postepy Hig. Med. Dosw., 2009; 63; 340-350.
25. Safarinejad M., Safarinejad S., Shafiei N. et al.: Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: Evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol.Carcinog., 2012; 6; w druku (doi: 10.1002/mc.21870).
26. Stachura J., Domagała W.: Patologia. Polska Akademia Umiejetności, 2005.
27. Steinberg G., Carter B., Beaty T. et al.: Family history and the risk of prostate cancer. Prostate, 1990; 17; 337-347.
28. Sutcliffe S., Giovannucci E., De Marzo A.M. et al.: Gonorrhea, syphillis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2006; 15; 2160-2166.
29. Taylor R., Cowin P., Cunha G. et al.: Formation of human prostate tissue from embryonic stem cells. Nat. Methods, 2006; 3; 179-181.
30. Tymchuk Ch., Barnard R., Ngo T. et al.: Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr. Cancer, 2002; 42; 112-116.
31. Vasto S., Carruba G., Candore G. et al.: Inflammation and prostate cancer. Future Oncol., 2008; 4; 637-645.
32. Wang W., Bergh A., Damber J.: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate, 2004; 61; 60-72.
33. Wojciechowska U., Didkowska J., Zatoński W.: Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii Instytut im. M. Skłodowskiej- Curie. Warszawa 2011.
34. Wright M., Chang S., Schatzkin A. et al.: Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer, 2007; 109; 675-684.